| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Chronic inflammation and oxidative stress in human carcinogenesis.
|
Int J Cancer
|
2007
|
3.45
|
|
2
|
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
|
J Clin Oncol
|
2012
|
3.04
|
|
3
|
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
|
Nat Rev Clin Oncol
|
2009
|
2.48
|
|
4
|
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma.
|
Cancer
|
2004
|
1.90
|
|
5
|
Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications.
|
Interact Cardiovasc Thorac Surg
|
2010
|
1.65
|
|
6
|
The use of xenograft models for the selection of cancer treatments with the EGFR as an example.
|
Crit Rev Oncol Hematol
|
2008
|
1.30
|
|
7
|
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
|
Clin Cancer Res
|
2010
|
1.15
|
|
8
|
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
|
Clin Cancer Res
|
2013
|
1.14
|
|
9
|
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis.
|
J Interferon Cytokine Res
|
2002
|
1.13
|
|
10
|
Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.
|
J Natl Cancer Inst
|
2005
|
1.11
|
|
11
|
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
|
Int J Cancer
|
2013
|
1.10
|
|
12
|
The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion.
|
Interact Cardiovasc Thorac Surg
|
2012
|
1.03
|
|
13
|
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
|
J Cell Physiol
|
2008
|
0.94
|
|
14
|
Control of post-thoracotomy pain by transcutaneous electrical nerve stimulation: effect on serum cytokine levels, visual analogue scale, pulmonary function and medication.
|
Eur J Cardiothorac Surg
|
2011
|
0.90
|
|
15
|
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials.
|
Lung Cancer
|
2010
|
0.88
|
|
16
|
Critical appraisal of the use of regorafenib in the management of colorectal cancer.
|
Cancer Manag Res
|
2013
|
0.87
|
|
17
|
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).
|
Oncol Rep
|
2004
|
0.84
|
|
18
|
Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study.
|
Cancer Invest
|
2010
|
0.84
|
|
19
|
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics.
|
Clin Lung Cancer
|
2007
|
0.83
|
|
20
|
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
|
Clin Cancer Res
|
2005
|
0.82
|
|
21
|
Emerging VEGF-receptor inhibitors for colorectal cancer.
|
Expert Opin Emerg Drugs
|
2012
|
0.81
|
|
22
|
Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer.
|
Expert Opin Investig Drugs
|
2012
|
0.80
|
|
23
|
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.
|
J Thorac Oncol
|
2015
|
0.78
|
|
24
|
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.
|
Expert Opin Investig Drugs
|
2014
|
0.78
|
|
25
|
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
|
J Thorac Oncol
|
2012
|
0.77
|
|
26
|
Epidermal growth factor receptor inhibitors in non-small-cell lung cancer.
|
Expert Opin Drug Discov
|
2007
|
0.76
|
|
27
|
Preoperative treatment of locally advanced esophageal carcinoma (Review).
|
Int J Oncol
|
2013
|
0.76
|
|
28
|
Combination of standard chemotherapy and targeted agents.
|
J Thorac Oncol
|
2007
|
0.76
|
|
29
|
Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?
|
Ther Adv Med Oncol
|
2013
|
0.75
|
|
30
|
Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care.
|
Core Evid
|
2007
|
0.75
|
|
31
|
Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?
|
Lung Cancer
|
2013
|
0.75
|
|
32
|
Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases.
|
Oncol Rep
|
2013
|
0.75
|